Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

  • ID: 4311868
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • MORE
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

Summary:

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 13 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease and Toxicology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Idiopathic Pulmonary Fibrosis, Diabetic Retinopathy, Fibrosis, Glioblastoma Multiforme (GBM), Pancreatic Cancer, Cardiovascular Disease, Chemotherapy Effects, Diabetic Macular Edema, Diabetic Nephropathy, Genital Warts (Condylomata Acuminata), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Liver Fibrosis, Malabsorption Syndrome, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) and Venous Leg Ulcers (Crural ulcer).

The latest report Integrin Alpha V - Pipeline Review, H1 2017, outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • MORE
  1. Introduction
  2. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview
  3. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development
  14. Biogen Inc
  15. BioMAS Ltd
  16. Factor Therapeutics Ltd
  17. MedImmune LLC
  18. Merck & Co Inc
  19. Merck KGaA
  20. SciFluor Life Sciences LLC
  21. Vascular Pharmaceuticals Inc
  22. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles
  23. 264-RAD - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. abituzumab - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. AC-301 - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. AS-101 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. BG-00011 - Drug Profile
  44. Product Description
  45. Mechanism Of Action
  46. R&D Progress
  47. C-16Y - Drug Profile
  48. Product Description
  49. Mechanism Of Action
  50. R&D Progress
  51. cilengitide - Drug Profile
  52. Product Description
  53. Mechanism Of Action
  54. R&D Progress
  55. CWHM-12 - Drug Profile
  56. Product Description
  57. Mechanism Of Action
  58. R&D Progress
  59. MK-0429 - Drug Profile
  60. Product Description
  61. Mechanism Of Action
  62. R&D Progress
  63. OCU-200 - Drug Profile
  64. Product Description
  65. Mechanism Of Action
  66. R&D Progress
  67. Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile
  68. Product Description
  69. Mechanism Of Action
  70. R&D Progress
  71. Proagio - Drug Profile
  72. Product Description
  73. Mechanism Of Action
  74. R&D Progress
  75. Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile
  76. Product Description
  77. Mechanism Of Action
  78. R&D Progress
  79. Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile
  80. Product Description
  81. Mechanism Of Action
  82. R&D Progress
  83. RSF-201 - Drug Profile
  84. Product Description
  85. Mechanism Of Action
  86. R&D Progress
  87. SF-0166 - Drug Profile
  88. Product Description
  89. Mechanism Of Action
  90. R&D Progress
  91. Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile
  92. Product Description
  93. Mechanism Of Action
  94. R&D Progress
  95. Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile
  96. Product Description
  97. Mechanism Of Action
  98. R&D Progress
  99. Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile
  100. Product Description
  101. Mechanism Of Action
  102. R&D Progress
  103. Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile
  104. Product Description
  105. Mechanism Of Action
  106. R&D Progress
  107. tetraiodothyroacetic acid - Drug Profile
  108. Product Description
  109. Mechanism Of Action
  110. R&D Progress
  111. VF-001 - Drug Profile
  112. Product Description
  113. Mechanism Of Action
  114. R&D Progress
  115. VPI-2690B - Drug Profile
  116. Product Description
  117. Mechanism Of Action
  118. R&D Progress
  119. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products
  120. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products
  121. Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones
  122. Featured News & Press Releases
  123. May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200
  124. Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update
  125. Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
  126. Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
  127. Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
  128. Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US
  129. Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board
  130. Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases
  131. May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find
  132. May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
  133. Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board
  134. Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease
  135. Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200
  136. Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
  137. Sep 26, 2014: Merck Serono to Present Data on Abituzumab at the ESMO
  138. Appendix
  139. Methodology
  140. Coverage
  141. Secondary Research
  142. Primary Research
  143. Expert Panel Validation
  144. Contact Us
  145. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Products under Development by Companies, H1 2017 (Contd..1), H1
  7. Number of Products under Investigation by Universities/Institutes, H1
  8. Products under Investigation by Universities/Institutes, H1
  9. Number of Products by Stage and Mechanism of Actions, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Pipeline by Biogen Inc, H1
  13. Pipeline by BioMAS Ltd, H1
  14. Pipeline by Factor Therapeutics Ltd, H1
  15. Pipeline by MedImmune LLC, H1
  16. Pipeline by Merck & Co Inc, H1
  17. Pipeline by Merck KGaA, H1
  18. Pipeline by SciFluor Life Sciences LLC, H1
  19. Pipeline by Vascular Pharmaceuticals Inc, H1
  20. Dormant Products, H1
  21. Dormant Products, H1 2017 (Contd..1), H1
  22. Dormant Products, H1 2017 (Contd..2), H1
  23. Dormant Products, H1 2017 (Contd..3), H1
  24. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • SciFluor Life Sciences LLC
  • Vascular Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll